These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 1708317)
21. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458 [TBL] [Abstract][Full Text] [Related]
22. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer]. Chen SB Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873 [TBL] [Abstract][Full Text] [Related]
23. [SC6 antigen for the diagnosis of pancreatic cancer before operation]. Guo XZ; Liu ZF; Ai R Zhonghua Yi Xue Za Zhi; 1993 Jan; 73(1):26-8, 61-2. PubMed ID: 8389232 [TBL] [Abstract][Full Text] [Related]
24. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Jiang XT; Tao HQ; Zou SC Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690 [TBL] [Abstract][Full Text] [Related]
25. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma]. Pei DP Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060 [TBL] [Abstract][Full Text] [Related]
26. Serum CA 242: the search for a valid marker of pancreatic cancer. Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807 [TBL] [Abstract][Full Text] [Related]
27. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354 [TBL] [Abstract][Full Text] [Related]
28. CEACAM1, a novel serum biomarker for pancreatic cancer. Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843 [TBL] [Abstract][Full Text] [Related]
30. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359 [TBL] [Abstract][Full Text] [Related]
31. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases. Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346 [TBL] [Abstract][Full Text] [Related]
32. [Monoclonal antibody SPan-1 in the diagnosis of exocrine pancreatic adenocarcinoma]. Frena A; Mazziotti A; La Guardia G; Martin F Chir Ital; 2000; 52(4):369-77. PubMed ID: 11190527 [TBL] [Abstract][Full Text] [Related]
33. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain. Kannagi R; Kitahara A; Itai S; Zenita K; Shigeta K; Tachikawa T; Noda A; Hirano H; Abe M; Shin S Cancer Res; 1988 Jul; 48(13):3856-63. PubMed ID: 2454154 [TBL] [Abstract][Full Text] [Related]
34. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Liao WC; Wu MS; Wang HP; Tien YW; Lin JT Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136 [TBL] [Abstract][Full Text] [Related]
35. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. DelMaschio A; Vanzulli A; Sironi S; Castrucci M; Mellone R; Staudacher C; Carlucci M; Zerbi A; Parolini D; Faravelli A Radiology; 1991 Jan; 178(1):95-9. PubMed ID: 1984331 [TBL] [Abstract][Full Text] [Related]
36. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases]. Czakó L; Takács T; Babarczy E; Dux L; Lonovics J Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648 [TBL] [Abstract][Full Text] [Related]
37. Limits of CEA and ferritin in the diagnosis of pancreatic cancer. Plebani M; Fabris C; Basso D; Del Favero G; Angonese C; Leandro G; Di Mario F; Burlina A; Naccarato R Int J Pancreatol; 1988; 3 Suppl 1():S113-7. PubMed ID: 3209864 [TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of serum CEACAM1 in patients with pancreatic cancer]. Gong DY; Fu HX; Peng Y; You YQ; Li ZP Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):164-6. PubMed ID: 21269981 [TBL] [Abstract][Full Text] [Related]
39. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma]. Nouts A; Lévy P; Voitot H; Bernades P Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189 [TBL] [Abstract][Full Text] [Related]
40. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer. Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]